ReviewJournal of the American Heart Association2023
Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer.
Review in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Comparative Safety and Efficacy of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Deep Vein Thrombosis (DVT) Treatment: A Meta-analysis.Cardiovascular drugs and therapy · 2025Pooled it
- Knowledge mapping and research trends on rehabilitation of patients with mechanical ventilation in the ICU from 2005 to 2024: a bibliometric analysis via CiteSpace and Bibliometrix.Frontiers in neurology · 2025Pooled it
- Research hotspots and frontiers in non-specific low back pain: a bibliometric analysis.Frontiers in neurology · 2024Pooled it
- A comparative study of EQ-5D-5L and SF-6D scales based on patients receiving oral anticoagulant therapy.Health and quality of life outcomes · 2026Article
- Visceral Embolic Events in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Incidence, Mortality, and Risk Prediction.Journal of clinical medicine · 2025Review
- Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis.Clinics and practice · 2025Article
- Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- A bibliometric analysis of the 50 most cited articles about quality of life in patients with atrial fibrillation.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- A Systematic Bibliometric Analysis of Cardiovascular Disease Risk in Obesity (2014-2024).Journal of multidisciplinary healthcare · 2025Review
- Trends in the Epidemiology of Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Surgery.Cureus · 2024Article
- Systematic bibliometric and visualized analysis of research hotspots and trends on the application of artificial intelligence in glaucoma from 2013 to 2022.International journal of ophthalmology · 2024Article
- Clinical Characteristics and Influencing Factors of New-Onset Atrial Fibrillation in Patients with Acute Pulmonary Embolism: A Case-Control Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Anticoagulation in venous thromboembolism and in atrial fibrillation.JRSM cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conjunction of atrial fibrillation (AF) and venous thromboembolism (VTE) is common in clinical practice. Over the last 2 decades, a significant number of articles (2500) have been published about AF and VTE. To effectively analyze and present these vast amounts of information, this study uses bibliometric research methods to categorize and consolidate these publications. The number of publications has increased yearly, especially since 2012. The United States was the most prolific country, with 1054 studies published. The most productive institution was McMaster University. Gregory Y.H. Lip was the most prolific author. The keyword analysis identified that the research focuses from 2003 to 2014 were factor Xa inhibitor, dabigatran etexilate, direct thrombin inhibitor, double-blind, deep vein thrombosis, molecular weight heparin, stroke prevention, etc. From 2015 to 2016, research mainly focused on venous thromboembolism, antithrombotic therapy, anticoagulant, warfarin, atrial fibrillation, stroke, and pulmonary embolism. Studies during 2017 to 2022 focused on apixaban, direct oral anticoagulant, rivaroxaban, dabigatran, hemorrhage, edoxaban, medicine efficacy and safety, risk factors, clinical management, and vitamin K antagonists. Since 2018, novel oral anticoagulants have been the most commonly used keywords. On the whole, most studies of AF and VTE focus on pathogenesis and therapeutic drugs. The causal relationship between AF and VTE, the effectiveness and safety of novel oral anticoagulants in the treatments, the anticoagulant regimen of AF and VTE co-disease, and the treatment regimen for vulnerable populations such as the elderly or obese people were the focus of current research and will continue to be the central point of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.